2012
Corrigendum to “The Significance of Perineural Invasion in Early-stage Cervical Cancer” [Gynecologic Oncology 123 (2011) 561–564]
ElSahwi K, Barber E, Illuzzi J, Buza N, Ratner E, Silasi D, Santin A, Azodi M, Schwartz P, Hui P, Rutherford T. Corrigendum to “The Significance of Perineural Invasion in Early-stage Cervical Cancer” [Gynecologic Oncology 123 (2011) 561–564]. Gynecologic Oncology 2012, 125: 770. DOI: 10.1016/j.ygyno.2012.02.026.Peer-Reviewed Original Research
2011
The significance of perineural invasion in early-stage cervical cancer
ElSahwi KS, Barber E, Illuzzi J, Buza N, Ratner E, Silasi DA, Santin AD, Azodi M, Schwartz PE, Rutherford TJ. The significance of perineural invasion in early-stage cervical cancer. Gynecologic Oncology 2011, 123: 561-564. PMID: 21968340, DOI: 10.1016/j.ygyno.2011.08.028.Peer-Reviewed Original ResearchConceptsEarly cervical cancerPerineural invasionCervical cancerRisk factorsAdjuvant therapyEarly-stage cervical cancer patientsEarly-stage cervical cancerMultiple high-risk factorsAdjusted hazard ratioIndependent risk factorRetrospective chart reviewLymphovascular space invasionCervical cancer patientsLarger tumor sizeHigh-risk factorsChart reviewHazard ratioCervical stromaParametrial invasionWorse prognosisPoor prognosisSpace invasionTumor sizeMean ageTumor extension
2003
Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy
Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecologic Oncology 2003, 91: 231-240. PMID: 14529687, DOI: 10.1016/s0090-8258(03)00460-8.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityEarly-stage cervical cancerStage cervical cancerCervical cancer cell linesCancer cell linesCervical cancerPrimary cell linesNeu expressionPrimary cervical cancer cell linesCell linesHER-2/neu expressionSite of recurrenceInhibition of proliferationEffector cellsMetastatic lesionsIL-2Primary treatmentTumor biopsiesCellular cytotoxicityHumanized mAbOriginal tumorRecurrent sitesLow dosesFlow cytometryLow expression